Literature DB >> 18569251

Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review.

Vanessa Taler1, Natalie A Phillips.   

Abstract

Mild cognitive impairment (MCI) manifests as memory impairment in the absence of dementia and progresses to Alzheimer's disease (AD) at a rate of around 15% per annum, versus 1-2% in the general population. It thus constitutes a primary target for investigation of early markers of AD. Language deficits occur early in AD, and performance on verbal tasks is an important diagnostic criterion for both AD and MCI. We review language performance in MCI, compare these findings to those seen in AD, and identify the primary issues in understanding language performance in MCI and selecting tasks with diagnostic and prognostic value.

Entities:  

Mesh:

Year:  2008        PMID: 18569251     DOI: 10.1080/13803390701550128

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  78 in total

1.  Analysis of verbal fluency ability in Alzheimer's disease: the role of clustering, switching and semantic proximities.

Authors:  Alyssa Weakley; Maureen Schmitter-Edgecombe
Journal:  Arch Clin Neuropsychol       Date:  2014-03-30       Impact factor: 2.813

2.  A Large-Scale Semantic Analysis of Verbal Fluency Across the Aging Spectrum: Data From the Canadian Longitudinal Study on Aging.

Authors:  Vanessa Taler; Brendan T Johns; Michael N Jones
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2020-10-16       Impact factor: 4.077

3.  Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment.

Authors:  Carrie R McDonald; Lusineh Gharapetian; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Dominic Holland; Anders M Dale
Journal:  Neurobiol Aging       Date:  2010-05-14       Impact factor: 4.673

4.  Connected Language in Late Middle-Aged Adults at Risk for Alzheimer's Disease.

Authors:  Kimberly Diggle Mueller; Rebecca L Koscik; Lyn S Turkstra; Sarah K Riedeman; Asenath LaRue; Lindsay R Clark; Bruce Hermann; Mark A Sager; Sterling C Johnson
Journal:  J Alzheimers Dis       Date:  2016-10-18       Impact factor: 4.472

5.  Longitudinal verbal fluency in normal aging, preclinical, and prevalent Alzheimer's disease.

Authors:  Linda J Clark; Margaret Gatz; Ling Zheng; Yu-Ling Chen; Carol McCleary; Wendy J Mack
Journal:  Am J Alzheimers Dis Other Demen       Date:  2009-09-16       Impact factor: 2.035

6.  Communication Difficulty and Relevant Interventions in Mild Cognitive Impairment: Implications for Neuroplasticity.

Authors:  Melissa Johnson; Feng Lin
Journal:  Top Geriatr Rehabil       Date:  2014-01

7.  Comparing the effects of clinician and caregiver-administered lexical retrieval training for progressive anomia.

Authors:  Stephanie M Grasso; Kaleigh M Shuster; Maya L Henry
Journal:  Neuropsychol Rehabil       Date:  2017-06-30       Impact factor: 2.868

8.  Is "Learning" episodic memory? Distinct cognitive and neuroanatomic correlates of immediate recall during learning trials in neurologically normal aging and neurodegenerative cohorts.

Authors:  K B Casaletto; G Marx; S Dutt; J Neuhaus; R Saloner; L Kritikos; B Miller; J H Kramer
Journal:  Neuropsychologia       Date:  2017-05-23       Impact factor: 3.139

9.  Voxel-wise co-analysis of macro- and microstructural brain alteration in mild cognitive impairment and Alzheimer's disease using anatomical and diffusion MRI.

Authors:  Valerie A Cardenas; Duygu Tosun; Linda L Chao; P Thomas Fletcher; Sarang Joshi; Michael W Weiner; Norbert Schuff
Journal:  J Neuroimaging       Date:  2013-02-19       Impact factor: 2.486

10.  Progressive logopenic/phonological aphasia: erosion of the language network.

Authors:  Jonathan D Rohrer; Gerard R Ridgway; Sebastian J Crutch; Julia Hailstone; Johanna C Goll; Matthew J Clarkson; Simon Mead; Jonathan Beck; Cath Mummery; Sebastien Ourselin; Elizabeth K Warrington; Martin N Rossor; Jason D Warren
Journal:  Neuroimage       Date:  2009-08-11       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.